Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Enanta Pharmaceuticals Highlights Promising Zelicapavir Pediatric Results And EDP-323 Post-Exposure Prophylaxis Data For RSV At IDWeek 2025

Author: Benzinga Newsdesk | October 20, 2025 07:04am
  • Zelicapavir Results in Shortened Symptom Duration in Pediatric Patients
  • EDP-323 is Highly Effective in a Post-Exposure Prophylaxis Setting

Posted In: ENTA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist